Drug fails to curb heart bypass complications, but surgery gets safer

July 10, 2012

A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by researchers at Duke University Medical Center.

But the international study also produced a surprising silver lining. As reported in the July 11 issue of the , the researchers discovered that complications among patients were far less frequent than previously reported.

"We expected about 10 percent of patients were at high risk for complication following grafting," said Mark F. Newman, M.D., chairman of the Department of at Duke and lead author of the study. "But the actual risk was 5 percent. What that means is has gotten much safer, even for high-risk patients."

Newman said surgical management of patients undergoing (CABG) has improved worldwide in the past decade.

The study, which began in 2009, tested a drug called acadesine in a trial that was one of the largest involving a surgical procedure. The primary objective was to determine whether acadesine would cut the rate of complications from CABG – the most common type of open heart surgery in the United States. The procedure is highly successful in restoring blood flow to the heart caused by blockages, but strokes, ventricular damage and death can result even after successful surgery.

One cause of complications is called ischemia reperfusion injury, which stems from changes that occur to tissue starved of oxygen during the surgery, when blood vessels are clamped to establish the grafts. This period of oxygen deprivation triggers inflammation and cell once blood flow is restored.

Earlier evidence from smaller studies suggested acadesine, given before, during and after surgery, could offer protection by easing some of the inflammatory responses that kill cells. Most of those studies occurred before 1997, however, when the rate of serious complications was 10 percent or greater.

Newman and colleagues at 300 sites in seven countries randomly assigned patients to receive the trial drug or a harmless placebo, and provided followup for a month. The group found that the drug was no better than placebo at protecting people from complications, with five percent of patients having a severe event within that month regardless of taking acadesine or a mock treatment. The study, funded by the manufacturer Merck, was halted early based on a prespecified interim analysis after 3,080 patients were enrolled.

Still, the 5 percent complication rate was good news, Newman said. It is likely the result of improved surgical methods in recent years, including better anesthesia and advances in surgical and heart-lung machine management.

"A lot of things have played a part in the gradual improvement of outcomes over the years," Newman said. "We wish we had a drug that could help with ischemia/reperfusion injury – and that remains something that would benefit patients tremendously -- but we have made strides in other areas. As a result, older, sicker patients are now undergoing cardiac surgery with very good results."

Newman also said that support for publication of a negative study by the sponsor, Merck, and by the publisher JAMA, is an important step in defining the appropriate therapy for heart going forward.

Explore further: Beating heart surgery may increase risk to patients

Related Stories

Beating heart surgery may increase risk to patients

March 14, 2012
Coronary artery bypass surgery performed whilst the heart is still beating may carry an increased likelihood of death, according to a systematic review by Cochrane researchers. The researchers suggest beating heart surgery ...

Drug helps maintain platelet inhibition and anti-clotting levels prior to cardiac surgery

January 17, 2012
Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate ...

Open heart surgery for kidney disease patients

May 17, 2012
One type of open heart surgery is likely safer than the other for chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Recommended for you

How genes and environment interact to raise risk of congenital heart defects

October 19, 2017
Infants of mothers with diabetes have a three- to five-fold increased risk of congenital heart defects. Such developmental defects are likely caused by a combination of genetic and environmental factors. However, the molecular ...

Mouse studies shed light on how protein controls heart failure

October 18, 2017
A new study on two specially bred strains of mice has illuminated how abnormal addition of the chemical phosphate to a specific heart muscle protein may sabotage the way the protein behaves in a cell, and may damage the way ...

Newborns with trisomy 13 or 18 benefit from heart surgery, study finds

October 18, 2017
Heart surgery significantly decreases in-hospital mortality among infants with either of two genetic disorders that cause severe physical and intellectual disabilities, according to a new study by a researcher at the Stanford ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

Blood cancer gene could be key to preventing heart failure

October 16, 2017
A new study, published today in Circulation, shows that the gene Runx1 increases in damaged heart muscle after a heart attack. An international collaboration led by researchers from the University of Glasgow, found that mice ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.